Clinical Study Of The Perio-ibuprofen Compound For Treatment Of Chronic Periodontitis

Objective:A large number of studies have shown that what the periodontal tissues of periodontitis have been most affected is the alveolar bone absorption. The absorption of alveolar bone has not only been related to the disease-causing microorganisms invading periodontal tissues, but also to a variety of bone resorption factors generated from the host defense response. Prostaglandins (PGs) is one type of factors that promote the bone resorption more, so using drugs that inhibit the synthesis of prostaglandins is a new research direction to periodontal treatment. NSAIDs (non-steroid-anti-inflammatory dugs) are a class of non-steroid drugs that inhibit prostaglandins to be produced. These drugs control periodontitis by inhibiting the synthesis reaction of prostaglandins. Ibuprofen is a type of NSAIDs. The mainly mechanism of ibuprofen is the reduction of PGs synthesis, periodontal inflammation and alveolar bone absorption by the inhibition of cyclooxygenase, so as to achieve the role of treatment of periodontitis. In this study, after scaling and root planing, we applicated periocline joint ibuprofen of non-steroid drugs locally as the auxiliary treatment of periodontitis and evaluated the clinical effects on the treatment of chronic periodontitis.MethodsOne hundred teeth of 50 patients suffering chronic periodontitis, whom come from our hospital during Sep 2008-Aug 2009, were chosen as the objects of this study. Each patient has two teeth similar of oral disease as self-control. All objects of study informed consent and meet the following conditions:①Have not systematic diseases;②Have not taken the antibiotic and non-steroid-anti-inflammatory drugs in 3 months;③Have not taken periodontal therapy in 1 year;④Feminine no pregnancy and no breast-feeding;⑤no history of allergies of the tetracycline class of antibiotics and non-steroidal drugs;⑥no smoking history.Sustained-release Periocline-ibuprofen compound was manufactured by adding a certain amount of ibuprofen (10%) to periocline as a sustained-release carrier. The two teeth in each patient were divided into experiment group and control group randomly. After scaling and root planning, the Periocline-ibuprofen compound was injected into the periodontal pockets in the experiment group every week for two times in all. While Periocline was injected into the control group Bleeding index (BI), probing depth (PD) and attachment level (AL) of the two groups were observed by a professional periodontist who was blinded for the study.ResultsThere was no significant difference (P>0.05) in the clinical index BK PD and AL between the experiment group and the control group at baseline. The clinical index BI of both groups at the first and second week of therapy was significantly lower than the baseline (P<0.05); The clinical index BI of the experiment group was significantly lower than the control group (P<0.05), while at the second week of therapy there was no significant difference (P>0.05) between the both groups. There were significant differences in the clinical index of PD not only between the both groups and the baseline at the first and second week of therapy, but also between the experiment group and the control group (P<0.05). The clinical index PD of both groups at the first and second week of therapy was obviously lower than the baseline(P<0.05),and the clinical index PD of the experiment group was also obviously lower than the control group(P<0.05).There was no significant difference (P>0.05) in the clinical index AL between the control group and the baseline at the first and second week of therapy, and there was also no significant difference (P>0.05) in the clinical index AL between the experiment group and the baseline at the first week of therapy. Meanwhile, there was significant difference (P<0.05) between the experiment group and the control group at the second week of therapy.ConclusionThis study has shown that Perio-ibuprofen compound can efficiently control the gingival inflammation and reduce the damage in chronic periodontitis at the early time of medication in the treatment of chronic periodontitis. There is a better clinical effect in reducing periodontal pocket depth and attachment loss.